-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Sector Analysis
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later...
-
Product Insights
Diffuse Large B-Cell Lymphoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Diffuse Large B-Cell Lymphoma Clinical Trials Market Report Overview The Diffuse Large B-Cell Lymphoma clinical trial market research report provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...